---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093356"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:01:32.559702+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptevo posts Q2 net loss $5.9M, cash $8.1M; APVO436 Phase 1b/2 trial to begin

## Summary
- Net loss of $5.9M ($1.67/sh) vs $7.9M ($53.95/sh) in Q2 2023; R&D spend down 33% to $3.6M.
- Cash $8.1M at June 30; proforma $10.4M including $2.75M July direct offering, extending runway into 2025.
- APVO436 Phase 1b/2 dose optimization trial for AML expected to start in Q3 2024; prior expansion showed 91% clinical benefit rate.
- ALG.APV-527 solid-tumor trial >90% enrolled; data showed durable stable disease in two heavily pretreated breast cancer patients.
- Max tolerated dose not yet reached for ALG.APV-527; dosing continues in cohort five.

## SEC filing metadata
- accession: 0000950170-24-093356
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017024093356/0000950170-24-093356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017024093356/apvo-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093356
- JSON: https://secwatch.observer/filing/0000950170-24-093356.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093356.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.